



# Connection, *EMBODIED*: Body Image and Intimacy Changes During and After Cancer Treatment

MAGGIE ELLINGS, DNP, ARNP, FNP-BC, AOCNP

EASE CANCER FOUNDATION BOARD MEMBER

CONFLUENCE HEALTH CANCER SURVIVORSHIP COORDINATOR

UNIVERSITY OF WASHINGTON SCHOOL OF NURSING DNP-FNP FACULTY

# Objectives

- ▶ Understand how impaired body image, intimacy issues, and sexual dysfunction are side effects of cancer diagnosis and treatment
- ▶ Define Body Image and Body Dysmorphia
- ▶ Describe the most common symptoms associated with sexual dysfunction during and after cancer treatment
- ▶ Learn to manage the short- and long-term effects that impact sexual health
- ▶ Grow in our connection to ourselves and our partners

# Body Image

- ▶ Body Image = The mental representation an individual creates of themselves, but it may or may not bear any relation to how one actually appears.
- ▶ A combination of thoughts and feelings you have about your body. May be positive and negative at different times or both at the same time.
- ▶ Personal Exercise:
  - ▶ Think of 3 things you like about your body and 3 things you don't like.
  - ▶ Now think about them all, are they mental representations (based on culture, society, social media, others' comments, childhood trauma, etc.) or are they actually how you appear (FACTS)?
  - ▶ If some are actually related to how you appear are they A) Something that you believe is good or bad? B) How do you know that they are good/bad? C) Do you want to, or can you even, change them?

# Body Dysmorphia

- ▶ A disabling preoccupation with perceived defects or flaws in appearance. It affects all genders and can make sufferers excessively self-conscious.
- ▶ People with body dysmorphia often drastically change behavior and thoughts over a fear of their perceived flaws.
  - ▶ Covering up perceived defects (heavy makeup over a scar/birthmark)
  - ▶ Self-conscious in social situations
  - ▶ Avoidance behavior- avoid work gatherings, school, dating, family outings, beaches/pools
  - ▶ Pursuit of obsessive cosmetic treatments
  - ▶ Agoraphobia- Fear of leaving home
  - ▶ Eating Disorders can develop or excessive dieting

# Cancer Survivors and Body Image

Any cancer treatment can lead to disordered body image:

- ▶ Body alterations- mastectomy, alopecia (hair loss), surgical ostomy, glossectomy, neck dissection, lymphedema, skin discoloration, incontinence, loss of mobility, scarring
- ▶ Pain
- ▶ Fatigue and poor quality sleep
- ▶ Hormone changes- AI/tamoxifen therapy, ADT, TAH/BSO
- ▶ Depression or Anxiety
- ▶ Weight loss or weight gain
- ▶ Sexual functioning

## Intervention for Body Image Issues

- ▶ CBT = Cognitive-Behavioral Therapy
- ▶ Psychosexual therapy
- ▶ Expressive-supportive therapy
- ▶ Education interventions
- ▶ Physical fitness Intervention
- ▶ Sensate-focused Intervention



This Photo by Unknown Author is licensed under [CC BY-NC](https://creativecommons.org/licenses/by-nc/4.0/)

# Sexual Health

## Sexual HEALTH

- ▶ A state of physical, emotional, mental and social well-being in relation to sexuality
- ▶ Sexuality is a natural part of life and involves more than sexual behavior
- ▶ Respecting sexual rights
- ▶ Access to sexual health information and education
- ▶ Ability to communicate about sexual health with partners and providers

## Sexual DYSFUNCTION

- ▶ 4 categories: Disorders of sexual desire/interest, arousal, orgasm, and sexual pain
- ▶ Any problem that prevents a person from experiencing satisfaction from sexual activity (again, subjective and individualized)
- ▶ Examples: asexuality, anorgasms, ED, delayed ejaculation, vaginal atrophy, decreased libido, dyspareunia (pain)

# Contributors to Sexual Dysfunction

## **Cancer Survivors:**

Disease Itself

Surgery

Chemotherapy

Radiation

Hormone Therapy

Supportive Medications

Transplant-GVHD

Menopause

Fatigue, pain, medication s/e, depression




# Disease Itself: Cancer


- ▶ Depending on where the tumor is, sexual function can be compromised



Stages IIA1 and IIA2 Cervical Cancer



Stage IIB Cervical Cancer



# Surgery

Dysfunction depends on the type of surgery performed:

- ▶ Mastectomy: decreased interest in sex, distorted body image
- ▶ Rectal Surgery: Injury to autonomic nerves in pelvis
- ▶ Prostatectomy: Radical, damages nerves that direct blood flow into the penis
- ▶ TAH and/or BSO: Orgasmic problems, dyspareunia, lack of sexual interest, decreased lubrication
- ▶ Vulvectomy: causes morbidity, vaginal tissue sparing surgeries help but are not predictors of sexual function
- ▶ Abdominoperineal Resection: Dyspareunia, pelvic adhesions and scarring

# Chemotherapy

- ▶ Associated with loss of desire due to N/V, diarrhea, constipation, mucositis, weight changes, fatigue
- ▶ Cytotoxic agents associated with vaginal dryness, dyspareunia, reduced ability to reach orgasm
- ▶ Can cause premature ovarian failure- vaginal atrophy, thinning of vaginal tissue, loss of elasticity, decreased lubrication
- ▶ Neurotoxic chemotherapies have been associated with decreased ejaculation of semen

# Radiation

- ▶ Can produce its own physical s/e: fatigue, N/V, diarrhea, etc.
- ▶ Prostate: damages arterial system transporting blood to penis, estimated 15-33% of men recover fully functional erections s/p external beam
- ▶ Pelvic: both external and implanted shown to damage the vaginal epithelium and basal layer of the mucosa → vaginal stenosis and vascular fibrosis
- ▶ Longitudinal prospective study s/p cervical radiation, 85% reported low or no sexual interest, 35% reported mod-severe lack of lubrication, 30% dissatisfied with sexual life

# Hormone Therapy

- ▶ Androgen therapy: Androgens act in the brain to promote sexual desire, reduced circulating androgens lead to decreased sexual interest and erectile dysfunction
- ▶ Tamoxifen: Associated with vaginal dryness/itching, soreness, occasional decrease in sexual desire and orgasmic delay
- ▶ Tamoxifen: Can increase rate of VMS by about 10%
- ▶ Aromatase Inhibitors: Strongly associated with vaginal dryness/itching, decreased sex drive

# Stem Cell Transplant

- ▶ GVHD- especially chronic can lead to loss of desire, ED associated with autonomic neuropathy
- ▶ Allo HSCTs have been implicated in causing genital GVHD, HPV reactivation, ovarian failure, infertility, sexual dysfunction



# “Vaginal Dryness”

- ▶ AKA: Vaginal atrophy, Genitourinary Syndrome of Menopause
- ▶ Drop in estrogen hormone (drastic, sudden) = less lubrication and less stretchable vagina. May become shorter and tighter at opening
- ▶ Causes for sudden estrogen drop for cancer survivors
  - ▶ GYN surgeries- oophorectomy
  - ▶ Aromatase Inhibitor or Tamoxifen use (5-10 years duration)
  - ▶ Radiation therapy that damages ovaries
  - ▶ Hypothalamic amenorrhea (excessive stress, not getting enough nourishment)
  - ▶ Chemotherapy- Anthracycline (daunorubicin, doxorubicin), cyclophosphamide, paclitaxel, platinum regimens (cisplatin, carboplatin, oxaliplatin)
  - ▶ Ovarian Suppression: drugs (leuprolide or goserelin)

# Treating Vaginal Dryness

- ▶ Vaginal moisturizers for longer-term relief from dryness
  - ▶ Replens, Good Clean Love BioNourish, Revaree, Hyalo Gyn
  - ▶ Vitamin E or Coconut oil (do not use petroleum jelly/Vaseline)
  - ▶ Use 3-5 times per week, disposable applicator, suppository, or directly on vulva
- ▶ Regular sexual activity or stimulation promotes vaginal health and blood flow
- ▶ Vaginal/vulva lubricants for temporary relief of dryness immediately before and during sexual intercourse
  - ▶ Good Clean Love, Aliquid, Astroglid, K-Y Jelly, Ah! Yes
  - ▶ Steer clear of any scented, colorful, warming/cooling products or those containing parabens
- ▶ Low dose vaginal estrogen therapy in cream or vaginal tablet form



# Erectile Dysfunction

- ▶ Surgery: disrupts the nerves close to the prostate that control blood flow to the penis. Can still occur with “nerve-sparing surgeries” but at lesser rate
- ▶ Radiation: prostate, bladder, colon and rectal cancers in particular
- ▶ Hormone therapy: ADT causes ED and loss of sexual desire
- ▶ Chemotherapy: Cisplatin, vincristine, paclitaxel, bortezomib, thalidomide can damage nerves
- ▶ Stem cell transplant: Often high doses of chemotherapy used. GVHD, loss of testosterone.

# Treating ED

## Drugs

### Pills

-Avanafil, sildenafil, tadalafil, vardenafil

### Injections

-Alprostadil; Very thin needle puts drug into the side of the shaft a few min prior to sexual activity

### Pellets

-Medicated urethral system for erection (MUSE)

-Placed into the urethra after urinating then massage penis to absorb drug

## Devices/implants

### Vacuum Erection Devices (VED)

-Suction draws blood into penis

-Stretchy band placed at the base to maintain

### -Prosthesis

-2 or 3 piece inflatable cylinder implant

-Semi-rigid/non-inflatable implant

## Counseling

-Ideally with a certified sex therapist or alternatively with a psychologist, counselor or psychiatric NP.

-Relationship counseling for education and relationship stress

-If ED is exacerbated by stress, anxiety or depression

# Hot Flashes

- ▶ AKA: Vasomotor symptoms, hot flushes; night sweats
- ▶ Likely caused by change in the hypothalamus- the part of the brain that regulates temperature.
- ▶ Cancer related causes include:
  - ▶ Drugs: Tamoxifen, raloxifene, some antidepressants, steroids, opioids
  - ▶ Oophorectomy surgery
  - ▶ Surgical removal of testes
  - ▶ Chemotherapy
  - ▶ Radiation therapy
  - ▶ Gonadotropin-releasing hormone therapy or estrogen therapy

# Treating Hot Flashes

- ▶ Estrogen is still the gold standard treatment for hot flashes. BUT, systemic estrogen not recommended for those who have had estrogen positive cancer
- ▶ Lifestyle changes: wearing layers, avoiding triggers (spicy food, alcohol, caffeine), relaxation exercises, cooling room temp and sleeping temp
- ▶ Herbal supplements: tofu/soy, black cohosh (research is mixed; inform provider)
- ▶ Paroxetine- SSRI antidepressant
- ▶ Bazedocifene is a SERM Selective Estrogen Receptor Modulator used for osteoporosis combined with conjugated estrogens though can be used for VMS.
- ▶ Fezolinetant (2023) tablets are non-hormone, FDA approved to target neurons in the hypothalamus to reduce heat signals that trigger VMS. In the randomized control trial research study fezolinetant did not show any clear trends in altering sex hormones

NON-HORMONAL PHARMACOLOGIC TREATMENTS AND DOSING<sup>a</sup>

| Class                        | Drug  | Commonly Used Daily Dose for Management of Vasomotor Symptoms                                   | Comments (For maximum benefit, may increase to higher doses after a week as tolerated)   |
|------------------------------|---|---|--|
| Antidepressants <sup>b</sup> | Venlafaxine <sup>c</sup> (SNRI) (preferred) | 75 mg   | Start at lowest dose possible (25 mg or 37.5 mg) and increase as tolerated   |
|                              | Desvenlafaxine (SNRI)                       | 100 mg  | Start at lowest dose possible (25 mg or 50 mg) and increase as tolerated   |
|                              | Escitalopram (SSRI)                         | 20 mg   | • Start at lowest dose possible (10 mg) and increase as tolerated  |
|                              | Citalopram (SSRI)                           | 20 mg   | • Start at lowest dose possible (10 mg) and increase as tolerated  |
|                              | Sertraline (SSRI) <sup>d</sup>              | 50 mg   | • Start at lowest dose possible (25 mg) and increase as tolerated<br>• Limited data on effectiveness<br>• Use with caution for survivors on tamoxifen  |
|                              | Paroxetine (SSRI) <sup>d</sup>              | Low-dose 7.5 mg or Standard paroxetine short acting up to 20 mg, controlled release up to 25 mg | • Low-dose (7.5 mg) paroxetine is the only FDA-approved alternative to hormones for hot flashes<br>• Use with caution for survivors on tamoxifen       |
|                              | Fluoxetine (SSRI) <sup>d</sup>              | 20 mg   | • Start at lowest dose possible (10 mg) and increase as tolerated<br>• Limited data on effectiveness<br>• Use with caution for survivors on tamoxifen  |
| Anti-convulsant              | Gabapentin <sup>c</sup> (preferred)         | 900 mg (typically 300 mg 3 times a day)   | • Start at lowest dose possible (100 mg or 300 mg) and increase as tolerated<br>• Consider starting at night time as this drug tends to cause sedation |
|                              | Pregabalin                                  | 150–300 mg  | Start at lowest dose possible (25 mg) and increase as tolerated  |
| Alpha-agonist hypertensive   | Clonidine                                   | 0.1 mg (oral or transdermal)  | Transdermal preparations may have fewer side effects   |

<sup>a</sup>For long-term care or maintenance and/or if lack of response, consider referral to appropriate health care specialist. A gradual tapering of dose rather than an abrupt discontinuation of drug is recommended when discontinuing these treatments.

<sup>b</sup>Anticipated clinical response of SSRIs/SNRIs for menopausal symptoms tends to be more rapid than the typical response for depression.


<sup>c</sup>Venlafaxine and gabapentin have been studied for the treatment of menopause symptoms in males, but data are limited. The other therapies have been used but not tested in males.

<sup>d</sup>SSRIs and in particular paroxetine block conversion of tamoxifen to active metabolites through CYP2D6.



# Body Image and Intimacy

- ▶ Most important = **EDUCATION**. Educate yourself about how your anatomy, how your body functions post treatment. Educate your partner and even family and friends if you desire.
- ▶ Create goals, be realistic about timing
- ▶ Communicate with your healthcare team and counselors
- ▶ Be open to resources available
- ▶ Be kind to yourself and gracious about your experience



# References

1. Body Image <https://www.psychologytoday.com/us/basics/body-image>. Accessed March 18, 2024
2. What is BDD? <https://bddfoundation.org>. Accessed March 18, 2024
3. Bober SL, Krapf J. Overview of Sexual-dysfunction in Female Cancer Survivors. <https://www-uptodate-com.offcampus.lib.washington.edu/contents/overview-of-sexual-dysfunction-in-female-cancer-survivors>. Topic Updated August 15, 2022. Accessed March 15, 2024.
4. Sexual health. WHO. [https://www.who.int/health-topics/sexual-health#tab=tab\\_1](https://www.who.int/health-topics/sexual-health#tab=tab_1)  
<https://www.ashasexualhealth.org/sexual-health/>. Accessed March 18, 2024.
5. Nesbakken N, Nygaard K, Bull-Njaa T, Carlsen E, Eri LM. Bladder and sexual dysfunction after mesorectal excision for rectal cancer. *Br J Surg*. 2000; 87(2):206-10. doi: 10.1046/j.1365-2168.2000.01357.x.
6. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. *Psycho-Oncology*. 2004;13(5): 295-308. doi: 10.1002/pon.744
7. Chorost M, Weber TK, Lee RJ, Rodriguez-Bigas MA, Petrelli NJ. Sexual dysfunction, informed consent and multimodality therapy for rectal cancer. *Am J Surg*. 2000;179(4):271-274. doi: 10.1016/s0002-9610(00)00327-5
8. Havenga K, Maas CP, DeRuiten MC, Welvaart K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. *Semin. Surg. Oncol*. 2000; 18(3):235-243.  
[doi.org/10.1002/\(SICI\)1098-2388\(200004/05\)18:3<235::AID-SSU7>3.0.CO;2-7](https://doi.org/10.1002/(SICI)1098-2388(200004/05)18:3<235::AID-SSU7>3.0.CO;2-7)

# References cont.

- ▶ 9. Montorsi F, Guazzoni-Luigi G, Strambi LF, Pozzo LFD, Nava L, Barbieri L, et al., Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective randomized trial. *Journal of Urology*. 1997; 158(4):1408-1410. [doi.org/10.1016/S0022-5347\(01\)64227-7](https://doi.org/10.1016/S0022-5347(01)64227-7)
- ▶ 10. Masui H, Ike H, Yamaguchi S, Oki S, Shimad H. Male sexual function after autonomic nerve-preserving operation for rectal cancer. *Dis Colon Rectum*. 1996; 39: 1140-1145 1996,
- ▶ 11. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Early-stage cervical carcinoma, radical hysterectomy, and sexual function. A longitudinal study. *Cancer*. 2004; 100(1):97-106. doi: 10.1002/cncr.11877
- ▶ 12. Andersen BL, Turnquist D, LaPolla J, Turner D. Sexual functioning after treatment of in situ vulvar cancer: preliminary report. *Obstet Gynecol*. 1998; 71(1):15-19. PMID: 3336539; PMCID: PMC2902361
- ▶ 13. Weijmar Schultz WC, Van de Wiel HBM, Bouma J, Janssens J, Littlewood J. Psychosexual functioning after the treatment of cancer of the vulva: A longitudinal study. *Cancer*. 1990; 66(2):402-407
- ▶ 14. Mirhashemi R, Averette HE, Lambrou N, Penalver MA, Mendez L, Ghurani G, Salom E. Vaginal reconstruction at the time of pelvic exenteration: a surgical and psychosexual analysis of techniques. *Gynecol Oncol*. 2002; 87(1)39-45. [doi.org/10.1006/gyno.2002.6780](https://doi.org/10.1006/gyno.2002.6780)
- ▶ 15. Fingeret MC, Teo I, Epner DE. Managing Body Image Difficulties of Adult Cancer Patients: Lessons from Available Research. *Cancer*. 2014; 120(5):633-641. doi: [10.1002/cncr.28469](https://doi.org/10.1002/cncr.28469)
- ▶ Managing Body Image Difficulties of Adult Cancer Patients: Lessons from Available Research



# References cont.

- ▶ 16. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. *J Sex Med.* 2007; 4(1):241-250. doi: 10.1111/j.1743-6109.2007.00409.x.
- ▶ 17. Broeckel JA, Thors C, Jacobsen PB, Small M, Cox CE. Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. *Breast Cancer Res Treat.* 2002; 75(3):241-248.
- ▶ 18. Morales L, Neven P, Timmerman D, Christiaens, M-R, Vergote I, Ban Limbergen E, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. *Anticancer Drugs.* 2004; 15(8):753-60
- ▶ 19. Burwell SR, Case D, Kaelin C, Avis N. Sexual problems in younger women after breast cancer surgery. *J Clin Oncol.* 2006; 24(18):2815-2821
- ▶ 20. Ganz PA, Greendale GA, Petersen L, B, Bower J. Breast cancer in younger women: reproductive and late health effects of treatment. *J Clin Oncol.* 2003; 21(22):4184-4193. doi: 10.1200/JCO.2003.04.196
- ▶ 21. Stanford JL, Feng Z, Hamilton AS. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer. *JAMA.* 2000; 283(3):354-360. doi:10.1001/jama.283.3.354
- ▶ 22. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. *International Journal of Radiation Oncology.* 2002; 54(4):1063-1068. doi: 10.1016/S0360-3016(02)03030-4
- ▶ 23. Jensen PT, Groenvold M, Klee MC, Thranov I, Morten AP, Machin D, et al. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. *International Journal of Radiation Oncology Biology Physics.* 2003; 56(4):937-949
- ▶ 24. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. *JNCI.* 2002; 94(6):430-437

# References cont.

- ▶ 25. Basaria S, Lieb J, Tang AM, DeWeese T, Carducci M, Eisenberger M, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. *Clinical Endocrinology*. 2002; 56(6):779-786.
- ▶ Mourits, Bockermann, de Vries, et al., 2002
- ▶ 26. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: Understanding women's health-related quality of life and sexual functioning. *Journal of Clinical Oncology*. 1998; 16(2):501-514.
- ▶ 27. Wong FL, Francisco L, Togawa K, Kim H, Bosworth A, Atencio L, et al. Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation. *Blood*. 2013; 122(24):3973-3981
- ▶ 28. Shanis D, Merideth M, Pulanic TK, Savani BN, Battiwalla M, Stratton P. Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management. *Semin Hematol*. 2012; 49(1):83-93. doi:10.1053/j.seminhematol.2011.10.002
- ▶ 29. Komisaurok BR, Rodriguez del Cerro MC. How does our brain generate sexual pleasure? *International Journal of Sexual Health*. 2021; 33(5):1-10. doi:10.1080/19317611.2021.1989534

# References cont.

- ▶ 30. Vaginal Discomfort. North American Menopause Society (NAMS). <https://www.menopause.org/for-women/sexual-health-menopause-online/causes-of-sexual-problems/vaginal-discomfort>. Accessed March 19, 2024.
- ▶ 31. Soewoto W, Agustriani N. Estradiol levels and chemotherapy in breast cancer patients: a prospective clinical study. *World J Oncol*. 2023; 14(1):60-66. doi: 10.14740/wjon1549
- ▶ 32. Ovarian Suppression. <https://www.komen.org/breast-cancer/treatment/type/hormone-therapy/ovarian-suppression>. Updated July 3, 2023. Accessed March 19, 2024.
- ▶ 33. Improving Your Vulvovaginal Health. <https://www.mskcc.org/cancer-care/patient-education/vaginal-health>. Updated February 8, 2023. Accessed March 19, 2024.
- ▶ 34. How Cancer Can Affect Erections. <https://www.cancer.org/cancer/managing-cancer/side-effects/fertility-and-sexual-side-effects/sexuality-for-men-with-cancer/erections-and-treatment.html>. Updated February 5, 2020. Accessed March 19, 2024.
- ▶ 35. Managing Male Sexual Problems Related to Cancer. <https://www.cancer.org/cancer/managing-cancer/side-effects/fertility-and-sexual-side-effects/sexuality-for-men-with-cancer/sex-problems.html>. Updated February 5, 2020. Accessed March 19, 2024.